Antibody-drug conjugates (ADCs) are a promising therapeutic strategy, with certain ADCs intentionally designed to deliver potent activity to both trophoblast cell-surface antigen 2 (Trop-2)–expressing cancer cells and to neighboring cancer cells through a bystander effect [6]. Here, TACSTD2 is linked to cancer.